A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions

MelanomaOvarian CancerSarcomaNon-small Cell Lung CancerBreast Cancer

Interventions

BIOLOGICAL

IDC-G305

NY-ESO-1 recombinant protein together with GLA-SE

Trial Locations (4)

Roswell Park Cancer Institute, Buffalo

H. Lee Moffitt Cancer Center, Tampa

Karmanos Cancer Institute, Detroit

Scottsdale Healthcare, Scottsdale

All Listed Sponsors

lead

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02015416 - A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | Biotech Hunter | Biotech Hunter